COMBINED MODALITY TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


COMBINED MODALITY TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A368 1991. Unique Identifier : AIDSLINE ICDB/91671387
DeAngelis LM; Yahalom J; Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Abstract: From 1985-1990, 32 non-AIDS patients (pts) with PCNSL were treated with a combined modality regimen using preradiation systemic methotrexate (1 g/m2) and intra-Ommaya methotrexate followed by 4000 cGy whole brain radiation (RT) with a 1440 cGy boost to the tumor bed. RT was followed by 2 courses of high-dose cytosine arabinoside (ARA-C); each course consisted of 2 doses of 3 g/m2 ARA-C separated by 24 hr. During this period, 16 additional pts with identical disease characteristics who either refused chemotherapy (CT) or started RT before our consultation were treated with cranial RT alone. All pts were staged at diagnosis; none had evidence of systemic disease. 5/48 had ocular lymphoma and 16/48 (33%) had definite meningeal involvement. Follow-up data is through September 1990. The median time to relapse was 40 mo for pts treated with RT plus CT vs 10 mo with RT alone (p = 0.007). The median survival time was 42 and 21 mo, respectively, compared to historical controls of 15-18 mo with RT alone. At recurrence 8 RT only pts received CT; 7 responded, but only 2 were alive 6 mo after treatment. The addition of CT to cranial RT for the initial treatment of PCNSL prolongs survival. Treatment with RT and withholding CT until recurrence does not improve survival over RT alone.
Keywords: Brain Neoplasms/*DRUG THERAPY/MORTALITY/RADIOTHERAPY Combined Modality Therapy Comparative Study *Cranial Irradiation Cytarabine/ADMINISTRATION & DOSAGE Follow-Up Studies Human Lymphoma/*DRUG THERAPY/MORTALITY/RADIOTHERAPY Methotrexate/*ADMINISTRATION & DOSAGE Radiotherapy Dosage Survival Rate ABSTRACT

KWDbrainneoplasms/KWDdrugtherapy/mortality/radiotherapycombinedmodalitytherapycomparativestudyKWDcranialirradiationcytarabine/administration&dosagefollow-upstudieshumanlymphoma/KWDdrugtherapy/mortality/radiotherapymethotrexate/KWDadministration&dosageradiotherapydosagesurvivalrateabstract
910830
M9181010

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .